This forum is for the discussion of anything to do with Prostate Cancer. There are only four rules:
No fundraisers, no commercials (although it is OK to recommend choices of treatment or medical people based on your personal research; invitations to participate in third-party surveys are also acceptable, provided there is no compensation to YANA);
No harvesting e-mail addresses for Spam;
No insults or flaming - be polite and respectful at all times and understand that there may be a variety of points of view, all of which may have some validity;
Opinions are OK, but please provide as much factual evidence as possible for any assertions that you are making
Failure to abide by these simple rules will result in the immediate and permanent suspension of your posting privileges.
Since this is an International Forum, please specify your location in your post.
I'm starting Xtandi this Tuesday 10th may. Read all about side effects.Was diagnosed 8 years ago PSA 95 gleason 9 stage T3b. Psa doubling average every 13 months. Regular scans. Latest scan shows spread to pelvic bone. Any statistics to median time till new spread on xtandi.
Drug being funded by NHS.
Many thanks
Bill
I doubt if enough folk have been on enzalutamide in your situation for there to be the sort of stats you're seeking. I can only give tangential advice. I've been on a similar regime - abiraterone for two and a half years. That's a lot longer than most folk experience. Usually, the treatment is effective for a matter of months. So, I come back to Terry's maxim "the only rule with PCa is that there are no rules". The same applies to treatments, I think. I take comfort in what I've been told repeatedly by oncologists - when this treatment fails (not if) there are now lots of options for further treatment. That must be so in your case too.
